Need help? Text us and our team of experts will reply in minutes
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
BPC-157 + TB-500 Overview
The BPC-157 + TB-500 blend combines two synthetic peptides studied for their signaling pathway interactions. BPC-157 is known for its potential effects on molecular signaling, structural remodeling, and cytokine modulation, while TB-500 (a fragment of Thymosin Beta-4) is associated with epithelial modeling, angiogenesis, and extracellular matrix dynamics. Together, they may provide complementary activity across multiple pathways in controlled experimental settings.
History
The concept of the BPC-157 + TB-500 blend stems from parallel lines of peptide research tracing back to foundational discoveries in molecular biology. BPC-157, deriving from a natural protein fragment in gastric tissue, was first synthesized to investigate its signaling and remodeling effects on structural and epithelial systems. Meanwhile, Thymosin β-4 (Tβ4)—and its synthetic fragment TB-500—originated from the discovery of thymosins in the 1960s by Allan L. Goldstein and colleagues, leading to interest in Tβ4's role in extracellular matrix dynamics and pathway modeling.
BPC-157 Structure
CAS #: 137525-51-0
Molecular Formula: C₆₂H₉₈N₁₆O₂₂
Molecular Weight: 1419.556 g/mol
PubChem ID: 108101
TB-500 Structure
CAS #: 77591-33-4
Molecular Formula: C₆₂H₉₈N₁₆O₂₂
Molecular Weight: 1419.556 g/mol
PubChem ID: 108101
Research Findings
BPC-157 and TB-500 have been studied in structural, vascular, epithelial, and systemic models, with research exploring their effects on tendon-to-bone interface modeling, collagen organization, angiogenesis, molecular migration, and systemic signaling. These findings highlight their roles in matrix dynamics, vascular pathways, and pathway activity in preclinical settings.
Key Areas of Resarch:
Structural: Tendon-to-bone, collagen, matrix
Vascular: Angiogenesis, nitric oxide, remodeling
Epithelial: Migration, signaling, matrix
Systemic: Gastric, survival, pathway dynamics
Together, these findings suggest broad experimental applications for BPC-157 and TB-500 across multiple biological pathways. Their combined influence on collagen synthesis, vascular formation, cytokine modulation, and systemic signaling provides a versatile foundation for research into molecular remodeling, pathway dynamics, and experimental biology.
References
Goldstein A. et al. (2005). Discovery of thymosins and their biological role.
Goldstein A. L., Hannappel E. et al. (2012). Thymosin β4 and tissue regeneration.
Chang C-H. et al. (2011). Therapeutic potential of BPC-157 in musculoskeletal injury models.
Hsieh M-J. et al. (2017). Angiogenic and circulatory support effects of BPC-157.
Huang T. et al. (2015). Effects of BPC-157 on skin wound healing and inflammation.
Sikiric P. et al. (2018). Organ-protective and systemic effects of BPC-157.
Our Process
Text us, our dedicated team is here to help
Reach out and get a response within minutes.
Frequently Asked Questions
Everything you need to know about our products and processes.
What is the ratio of BPC-157 to TB-500 in each vial?
Are additional supplies needed?
How long does a vial last?
Does the product come with instructions?
How should I store these products?
Verified compounds.
Ready to ship.
Need help? Text us, and a team member will reply in minutes.
© DirectPeptides 2026. All rights reserved.
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Direct Peptides is a chemical supplier. Direct Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Direct Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption.